Becton, Dickinson and (BDX, Medical devices) Stock Valuation & Fair Value
Mixed on our testsBecton, Dickinson and (BDX, Medical devices) trades at a current P/E of 16.6, about 10% below its historical normal valuation, with a forward growth estimate of 6.2% and a PEG of 2.68. Analysts' one-year estimates have been hit 91% of the time. Priced at its historical normal P/E of 18.4 on the same blended earnings, the 2026-11-06 close of $211.88 corresponds to about $235 a share. This is a valuation reference, not a price target.
How to read these numbers: the PEG ratio and current P/E versus normal P/E.
- Price $211.88 at the Nov 6 close, 7.5% above the 20-day average ($197.15) and 12.7% above the 50-day ($188.06).
- RSI (14) at 74.6.
- 52-week range $136.40 to $213.55: the price is 0.8% below the high and 55.3% above the low.
The Street vs SeerForecast
Wall Street's mean price target for BDX is $195.57 across 14 analysts, 7.7% below the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: mixed on our tests. When the two disagree, start your digging there.
Valuation flags
- Overbought (RSI 75)
Verdict history
tickerseer's rating has been mixed on our tests since 2026-06-03.
Not every point was recorded live. Points marked recalculated are worked out from the metrics tickerseer archived that week.
Selected weeks: the first, the latest, and the cheapest and dearest.
Show all 45 readings
Frequently asked questions
Is Becton, Dickinson and stock overvalued?
At a current P/E of 16.6 versus its historical normal P/E of 18.4, Becton, Dickinson and trades about 10% below its typical valuation, with a PEG of 2.68 on 6.2% forward growth. tickerseer currently rates it mixed on our tests.
What is Becton, Dickinson and's fair value and PEG?
Becton, Dickinson and trades at a current P/E of 16.6 against a historical normal P/E of 18.4, a PEG of 2.68, and a forward growth estimate of 6.2%. Priced at its historical normal P/E of 18.4 on the same blended earnings, the 2026-11-06 close of $211.88 corresponds to about $235 a share. This is a valuation reference, not a price target.
Has tickerseer's rating of Becton, Dickinson and changed?
tickerseer's rating has been mixed on our tests since 2026-06-03.
What is the analyst price target for Becton, Dickinson and?
The mean Wall Street price target for Becton, Dickinson and is $195.57 across 14 analysts, 7.7% below the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.
Industry: Medical devices. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and an AI research note where we have one. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.